Opioids for chronic non-cancer pain

作者: R. Freynhagen , G. Geisslinger , S. A. Schug

DOI: 10.1136/BMJ.F2937

关键词: Clinical trialAnesthesiaCancer painOpioidIntensive care medicinePain ladderChronic painMedicineAdverse effectNeuropathic painBack pain

摘要: A 36 year old carpenter has a six month history of lower back pain with no specific clinical or radiological findings. As his not responded to paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs), he asks doctor if can have “stronger painkillers” such as morphine. Opioids are group compounds that act by binding opioid receptors (μ, κ, δ), which widely distributed in the brain, spinal cord, peripheral tissues. They mainstay management cancer pain, but published data show continual increase volume prescribed opioids manage moderate severe, chronic, non-cancer pain.1 2 Changes attitude aggressive marketing driven dramatic use, more adverse events, including deaths from overdose (now second leading cause accidental death US).3 Proponents claim underused for chronic pain,4 lack good scientific prevented formulation evidence based guidelines their especially primary care. Several meta-analyses effectiveness been published. Most randomised trials summarised these were funded pharmaceutical industry report heterogeneous, short term outcomes highly selected patients. Non-randomised uncontrolled observational studies make up rest literature. Nevertheless, most consistently shown some reducing intensity. In particular, efficacy neuropathic pain,5 6 7 although regard only third line treatment because risk:benefit profile.8 9 The even less encouraging non-neuropathic focus this paper. 2009 Cochrane review 10 quasi-randomised controlled compared …

参考文章(36)
Howard Cabral, Susan Jick, Soko Setoguchi, Lin Li, Opioids and risk of type 2 diabetes in adults with non-cancer pain. Pain Physician. ,vol. 16, pp. 77- 88 ,(2013) , 10.36076/PPJ.2013/16/77
Jørgen Eriksen, Per Sjøgren, Eduardo Bruera, Ola Ekholm, Niels K. Rasmussen, Critical issues on opioids in chronic non-cancer pain: an epidemiological study. Pain. ,vol. 125, pp. 172- 179 ,(2006) , 10.1016/J.PAIN.2006.06.009
R. Scharnagel, U. Kaiser, A. Schütze, R. Heineck, G. Gossrau, R. Sabatowski, Chronische nichttumorbedingte Schmerzen Der Schmerz. ,vol. 27, pp. 7- 19 ,(2013) , 10.1007/S00482-012-1278-6
Jennifer A. Elliott, MD, Erica Horton, DO, Eugene E. Fibuch, MD, The endocrine effects of long-term oral opioid therapy: A case report and review of the literature Journal of opioid management. ,vol. 7, pp. 145- 154 ,(2018) , 10.5055/JOM.2011.0057
Ramsin M. Benyamin, Christopher G. Gharibo, Timothy R. Deer, Stephanie Geffert, Dhanalakshmi Koyyalagunta, Ike Eriator, Jeffrey W. Janata, Kavita N. Manchikanti, Kimberly A. Cash, Lee T. Snook, Aaron K. Calodney, Michael E. Harned, Yogesh Malla, Carl C. Balog, Bert Fellows, Vidyasagar Pampati, Ramarao Pasupuleti, Carla D. McManus, Kim S. Damron, Mark V. Boswell, Allen W. Burton, David A. Bryce, Paul J. Christo, Joshua A. Hirsch, Deborah H. Tracy, Bradley W. Wargo, Sudhir Diwan, Sairam Atluri, David L. Caraway, Salahadin Abdi, Adam M. Kaye, Hans Hansen, Scott E. Glaser, Standiford Helm, Sanford M. Silverman, Howard S. Smith, Nalini Sehgal, Salim M. Hayek, Patricia A. Burks, Daneshvari R. Solanki, Alan D. Kaye, Haroon Hameed, Marion Lee, Sukdeb Datta, David S. Kloth, Jay S. Grider, Vikram B. Patel, Keith R. Brown, Vijay Singh, Frank J.E. Falco, Ricardo Vallejo, Allan T. Parr, Laxmaiah Manchikanti, Mariam Hameed, Brian M. Bruel, American Society of Interventional Pain Physicians (ASIPP) Guidelines for Responsible Opioid Prescribing in Chronic Non-Cancer Pain: Part 2 - Guidance Pain Physician. ,vol. 15, ,(2012)
Howard G. Birnbaum, Alan G. White, Matt Schiller, Tracy Waldman, Jody M. Cleveland, Carl L. Roland, Societal Costs of Prescription Opioid Abuse, Dependence, and Misuse in the United States Pain Medicine. ,vol. 12, pp. 657- 667 ,(2011) , 10.1111/J.1526-4637.2011.01075.X
Sebastiano Mercadante, Antonello Giarratano, None, Combined oral prolonged-release oxycodone and naloxone in chronic pain management Expert Opinion on Investigational Drugs. ,vol. 22, pp. 161- 166 ,(2013) , 10.1517/13543784.2013.752460